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Mortality Trends in Patients
Diagnosed With First Atrial Fibrillation
A 21-Year Community-Based Study
Yoko Miyasaka, MD, PHD, FACC,* Marion E. Barnes, MSC,* Kent R. Bailey, PHD,†
Stephen S. Cha, MS,† Bernard J. Gersh, MB, CHB, DPHIL, FACC,* James B. Seward, MD, FACC,*
Teresa S. M. Tsang, MD, FACC*
Rochester, Minnesota
Objectives The purpose of this study was to assess the mortality trends of atrial fibrillation (AF) in a community.
Background Limited data exist regarding the mortality trends of patients diagnosed with first AF.
Methods A community-based cohort of adult residents of Olmsted County, Minnesota, who had electrocardiogram-
confirmed first-documented AF in the years 1980 to 2000 were identified and followed to 2004 or death. The
primary outcome was all-cause mortality.
Results Of a total of 4,618 residents (mean age 73  14 years) diagnosed with first AF, 3,085 died during a mean
follow-up of 5.3  5.0 years. Relative to the age- and gender-matched general Minnesota population, the mor-
tality risk was increased (p  0.0001) with a hazard ratio (HR) of 9.62 (95% confidence interval [CI] 8.93 to
10.32) within the first 4 months and 1.66 (95% CI 1.59 to 1.73) thereafter. Cox proportional hazards modeling
showed no change in overall age- and gender-adjusted mortality (HR for the year 2000 vs. 1980: 0.99; 95% CI
0.86 to 1.13; p  0.84), even after adjustment for comorbidities. In secondary analyses, no changes in mortality
were seen for early (within first 4 months) or late (after 4 months) mortality for the entire group or within the
subgroup of patients who did not have cardiovascular disease at baseline.
Conclusions In this cohort of patients newly diagnosed with AF, mortality risk was high, especially within the first 4
months. There was no evidence for any significant changes over the 21 years in terms of overall mortality, early
or late mortality, or mortality among patients without pre-existing cardiovascular disease. (J Am Coll Cardiol
2007;49:986–92) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.062m
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atrial fibrillation (AF) is a growing public health problem
1), which has reached epidemic proportions (2–4). Our
ecent data provided evidence for a progressive increase in
ge-adjusted prevalence (5) as well as age-adjusted incidence
ver the past few decades (6). We projected that the number
f persons with AF in the U.S. will exceed 10 million by the
ear 2050 (6). Atrial fibrillation is a well established risk
actor for stroke (7–12), congestive heart failure (13–15),
nd premature death (14–18).
Considering the numerous changes in the management
f AF patients over the last 2 decades, both in terms of
reatment of AF itself (increased use of class 3 antiarrhyth-
rom the *Division of Cardiovascular Disease and Internal Medicine, and the
Section of Biostatistics, Mayo Clinic, Rochester, Minnesota. Dr. Tsang was
upported by an American Heart Association National Scientist Development Grant,
ational Institutes of Health grant RO1 AG 22070, and an American Society of
chocardiography Outcomes Research Grant.B
Manuscript received March 27, 2006; revised manuscript received October 19,
006, accepted October 23, 2006.ic drugs, use of warfarin for prophylaxis against thrombo-
mbolic events, and introduction of various device therapies
ncluding AF ablation) as well as increased aggressiveness in
oronary risk reduction in general, it is conceivable that the
ortality risk of AF patients may have changed over time.
ndeed, some studies have reported a decline in mortality
isk after AF (19–23). However, these studies were largely
ospital-based series of patients with any AF, and the findings
ould not provide an understanding of whether the overall
ortality risk of patients has changed over time when
ollowed longitudinally from first diagnosis. In the present
tudy, we analyzed the mortality trends in a well defined
ommunity-based cohort followed longitudinally from the
rst documented AF episode.
ethods
tudy setting. This community-based cohort study was
pproved by the Mayo Foundation Institutional Review
oard. Olmsted County, Minnesota, is well suited for the
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March 6, 2007:986–92 Trends in Mortality After First AFonduct of studies with long-term follow up because of a
umber of unique features (24). Geographically, the com-
unity is relatively isolated from other urban centers, and
edical care is delivered by only a few health care providers.
ost of the Olmsted County residents return to the Mayo
linic regularly, allowing capturing of events. An earlier
tudy has shown that 96% of Olmsted County women
esidents age 65 to 74 years returned to the Mayo Clinic
ithin a 3-year period (24). For each patient at the Mayo
linic, a unified medical record containing details of all
npatient and outpatient encounters is maintained. Within
ach medical record, diagnoses made during office visits,
linic consultations, emergency room visits, hospital admis-
ions, nursing home care, and autopsy examinations, as well
s surgical procedures, are listed on a master sheet and
oded. Coded diagnoses are then transferred to a central
iagnostic index. This diagnostic index allows all patients
ith a diagnosis of interest to be readily identified. An
lectronic electrocardiogram database has been established
t Mayo since 1976, allowing rapid identification of the
oded interpretation and diagnoses for each electrocardio-
ram. All electrocardiograms can also be retrieved for direct
eview.
ncident AF cohort. The medical records of Olmsted
ounty adult residents who had first AF documented
etween January 1, 1980, and December 31, 2000, in any of
he Mayo administrative databases (medical index, surgical
ndex, and electrocardiographic and echocardiographic da-
abases) were reviewed and followed forward in medical
ecords to March 2004 or death. We additionally confirmed
hat the presence of a 12-lead electrocardiogram showing
F was the very first documentation for each subject.
ecause the unit record system at Mayo dated back to the
arly 1900s, any electrocardiogram performed on any pa-
ient was contained within the unit record. Any AF that
ccurred before the establishment of the electronic data-
ases would have been identified from the chart review
rocess. Patients with atrial flutter alone and without any
vidence of AF, were not included. For the purpose of this
tudy, we did not specifically distinguish paroxysmal from
ersistent or permanent AF. All diagnoses, covariates, and
utcomes were defined a priori, and the same definitions
ere applied to all patients throughout the 21-year study
eriod.
utcome ascertainment. Ascertainment of death was ac-
omplished through comprehensive review of medical
ecords and through the use of the following resources:
eath certificates, Vital Status Information from Mayo
egistration, Minnesota State Death Tapes, and Social
ecurity Death Index.
tatistical analyses. TRENDS IN BASELINE CHARACTERIS-
ICS. Baseline characteristics were summarized by means
nd standard deviations or frequency percentages and as-
essed for trends across the calendar year of AF diagnosis
sing linear regression analyses for continuous variables and
ogistic regression analyses for binary variables, adjusting for cge and gender. Calendar year of
F diagnosis was treated as a
ontinuous variable. Only linear
r linear logistic trends in calen-
ar year of AF were considered.
ORTALITY AFTER FIRST AF DI-
GNOSIS. The cumulative sur-
ival after AF was estimated using the Kaplan-Meier
ethod. Based on Kaplan-Meier analyses, the mortality rate
as highest in the initial 4 months after the diagnosis of first
F but decreased progressively and appeared to plateau at
round the fifth month following first diagnosis. Therefore,
e chose the cut point of 4 months after first AF diagnosis
early mortality period) for the purpose of analyses owing to
he temporal profile and changes in mortality risk. The
elative mortality risk associated with incident AF, defined
s the hazard ratio (HR) between those with a diagnosis of
F and those in the Minnesota white population of the
ame age, gender, and calendar year, was analyzed both in
erms of overall mortality as well as separately in terms of
arly mortality period (within first 4 months) and late
ortality. First, observed and expected mortality were
lotted and compared using the 1-sample log rank test, with
xpected mortality calculated using the Vital Statistics
atabases and an in-house SAS macro (SAS Institute, Cary,
orth Carolina). Second, the relative hazard was estimated,
oth overall and within the 2 time periods (early mortality
eriod and late mortality), as the ratio of observed to
xpected deaths, with the numerator considered as a Poisson
ariable with expected value equal to the denominator, for
he purpose of constructing confidence intervals (CI).
RENDS IN MORTALITY AFTER FIRST AF DIAGNOSIS. For
isplay purposes, Kaplan-Meier survival curves were esti-
ated for each of the 4 periods 1980 through 1984, 1985
hrough 1989, 1990 through 1994, and 1995 through 2000.
he primary formal analyses examined the effects of age and
ender on mortality after AF diagnosis, and then the effect
f calendar year of AF diagnosis on mortality, controlling
or age and gender, using the Cox proportional hazards
odel for time to death, with age, gender, and calendar year
n the model. Two models were considered: a main effects
odel with age, gender, and calendar year entering addi-
ively, and a second model that considered, in addition, all
possible 2-way interactions among the 3 variables, with
nly significant interactions being retained.
Next, to explore trends in mortality adjusting for patient
aseline characteristics, multivariable Cox regression models
ere used, further adjusting the main effects model for a set
f baseline clinical variables. Clinical covariates selected for
djustment included age; gender; body mass index; heart
ate at AF diagnosis; and history of myocardial infarction,
ongestive heart failure, peripheral vascular disease, carotid
rtery disease, stroke, systemic hypertension, diabetes mel-
itus, smoking, regular alcohol use, chronic renal disease,
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
HR  hazard ratiohronic obstructive pulmonary disease, hyperthyroidism,
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Trends in Mortality After First AF March 6, 2007:986–92nd malignancy. We did not use valvular heart disease for
djustment in the multivariate models for the purpose of
ssessing trends in mortality. This was because the preva-
ence of valvular heart disease increased markedly over time,
espite the same definition used throughout the study
eriod, reflecting the major changes in practice with the use
f echocardiography.
Finally, to allow for the pronounced difference between
arly high mortality and late mortality, 3 supplementary
nalyses were performed, adjusting for baseline characteris-
ics. In the first, analysis was limited to the early high
ortality period of follow-up by censoring all patients at the
arly high mortality period. In the second, analysis was
imited to subjects who survived and were followed beyond
he early high mortality period. In the third supplementary
nalysis, with the goal of removing patients who were more
ikely to have early events, analysis was restricted to those
ithout earlier or concurrent cardiovascular history (conges-
aseline Characteristics of the Study Population, Stratified by Cale
Table 1 Baseline Characteristics of the Study Population, Stra
Variable
Overall
(n  4,618)
1980–198
(n  826
Age (yrs) 73.1  14.4 72.9  14
Men 2,365 (51) 412 (50)
BMI (kg/m2) 27.1  6.2 25.8  5.3
Systolic BP (mm Hg) 138  21 137  22
Diastolic BP (mm Hg) 78  11 78  11
Heart rate at AF (beats/min) 112  32 113  32
History of CAD 1,776 (38) 315 (38)
Prior myocardial infarction 962 (21) 189 (23)
Prior CHF 446 (9.7) 59 (7.1)
Concurrent CHF 884 (19) 206 (25)
Clinically diagnosed VHD 1,128 (24) 131 (16)
Echocardiographically confirmed VHD 969 (21) 46 (5.6)
Coronary revascularization 575 (12) 44 (5.3)
Peripheral artery disease 605 (13) 105 (13)
Carotid artery disease 208 (4.5) 26 (3.1)
Stroke 437 (9.5) 86 (10)
Systemic hypertension 3,694 (80) 580 (70)
Diabetes mellitus 844 (18) 154 (19)
Dyslipidemia 1,706 (37) 128 (15)
Smoking 2,592 (56) 431 (52)
Regular alcohol use 539 (12) 89 (11)
Chronic renal disease 782 (17) 150 (18)
COPD 1,000 (22) 192 (23)
Hyperthyroidism 47 (1.0) 10 (1.2)
History of malignancy 1,237 (27) 171 (21)
Angiotensin-converting enzyme inhibitor 504 (11) 5 (0.6)
Angiotensin receptor blocker 34 (0.7) 0 (0)
Calcium-channel blocker 666 (14) 25 (3.0)
Beta-blocker 687 (15) 89 (11)
Diuretics 1,705 (37) 335 (41)
Lipid-lowering therapy 222 (4.8) 2 (0.2)
alues are given as mean  SD or number (%). *p value for trends across calendar-year of AF di
ariables, with adjustment for age and gender.
AF atrial fibrillation; BMI body mass index; BP blood pressure; CAD coronary artery disease; CH
isease.ive heart failure, ischemic stroke, angina, angiographically
onfirmed coronary artery disease, or myocardial infarction).
REDICTORS OF DEATH IN PATIENTS WITH AF. In an at-
empt to understand the factors associated with mortality
isk, we evaluated the relationship between selected clinical
ariables and time to death by Cox modeling. The following
ariables were considered: age; gender; body mass index;
eart rate at AF diagnosis; and history of myocardial
nfarction, congestive heart failure, echocardiographically
onfirmed valvular heart disease, coronary revascularization,
eripheral vascular disease, carotid artery disease, stroke,
ystemic hypertension, diabetes mellitus, dyslipidemia,
moking, regular alcohol use, chronic renal disease, chronic
bstructive pulmonary disease, hyperthyroidism, and malig-
ancy . First, an overall model was estimated, describing the
R associated with each variable throughout time. In
ddition, a 2-phase time-dependent model was estimated,
Year of AF Diagnosis
by Calendar Year of AF Diagnosis
Calendar Year of AF Diagnosis
p Value*
1985–1989
(n  938)
1990–1994
(n  1,209)
1995–2000
(n  1,645)
72.8  14.1 73.0  14.7 73.4  14.3 0.07
469 (50) 629 (52) 855 (52) 0.08
26.2  5.5 27.2  6.3 28.0  6.6 0.0001
143  21 140  20 135  19 0.0001
80  10 79  11 75  11 0.0001
115  32 111  31 112  32 0.12
400 (43) 441 (36) 620 (38) 0.15
194 (21) 246 (20) 333 (20) 0.08
82 (8.7) 131 (11) 174 (11) 0.01
223 (24) 220 (18) 235 (14) 0.0001
217 (23) 304 (25) 476 (29) 0.0001
160 (17) 292 (24) 471 (29) 0.0001
83 (8.8) 154 (13) 294 (18) 0.0001
139 (15) 161 (13) 200 (12) 0.16
43 (4.6) 56 (4.6) 83 (5.0) 0.05
85 (9.1) 128 (11) 138 (8.4) 0.09
754 (80) 982 (81) 1,378 (84) 0.0001
148 (16) 227 (19) 315 (19) 0.28
245 (26) 451 (37) 882 (54) 0.0001
533 (57) 679 (56) 949 (58) 0.05
119 (13) 151 (12) 180 (11) 0.79
140 (15) 188 (16) 304 (18) 0.39
230 (25) 244 (20) 334 (20) 0.05
18 (1.9) 8 (0.7) 11 (0.7) 0.05
242 (26) 315 (26) 509 (31) 0.0001
27 (2.9) 157 (13) 315 (19) 0.0001
0 (0) 0 (0) 34 (2.1) 0.0001
98 (10) 198 (16) 345 (21) 0.0001
115 (12) 147 (12) 336 (20) 0.0001
364 (39) 429 (35) 577 (35) 0.01
6 (0.6) 30 (2.5) 184 (11) 0.0001
by linear regression analysis for continuous variables and logistic regression analysis for binaryndar
tified
4
)
.5
agnosisF congestive heart failure; COPD chronic obstructive pulmonary disease; VHD valvular heart
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March 6, 2007:986–92 Trends in Mortality After First AFn which each variable’s HR was allowed to vary between
he early high mortality period and late mortality. The HRs
n each time period were tested for departure from the null
ypothesis of no association, and the 2 HRs were further
ested for equality to each other. All tests of significance
ere 2 tailed, and a p value of 0.05 was considered to be
tatistically significant.
esults
he study population consisted of 4,618 subjects (mean age
3  14 years, range 18 to 107 years, 51% men) who were
onfirmed to have AF for the first time in the years 1980 to
000. Baseline characteristics stratified by calendar-year of
F diagnosis are displayed in Table 1.
ortality after first AF diagnosis. During a mean
ollow-up time of 5.3 5.0 years, 3,085 died. Of these, 761
ied within the first 4 months and 2,324 thereafter. The
aplan-Meier estimates of survival at 4 months, 1 year, 3
ears, and 5 years were 83% (95% CI 82% to 85%), 77%
95% CI 76% to 78%), 63% (95% CI 62% to 65%), and 52%
95% CI 51% to 54%), respectively. A high early mortality
ate (within first 4 months) followed by a flatter survival
urve after 4 months was evident (Fig. 1). Relative to age-
nd gender-matched general Minnesota population, the
ortality risk for AF patients was substantially higher (log
ank p  0.0001). The HRs were as follows: overall: 2.08
3,085 vs. 1,481.8 expected, 95% CI 2.01 to 2.16); within
he first 4 months: 9.62 (761 observed vs. 79.07 expected,
5% CI 8.93 to 10.32); and after the first 4 months: 1.66
2,324 observed vs. 1,402.8 expected, 95% CI 1.59 to 1.73)
Fig. 1). The most common causes of cardiovascular death
ere coronary artery disease, congestive heart failure, and
schemic stroke, accounting for 22%, 14%, and 10%, respec-
ively, of the early deaths (within first 4 months) and 15%,
6%, and 7%, respectively, of the late deaths. The most
ommon noncardiovascular cause of death was malignancy,
Figure 1 Survival for AF Patients Compared With the
Age- and Gender-Matched General MN Population
Survival for the entire study population of patients diagnosed with first atrial
fibrillation (AF) (left) and for the subgroup of survivors who lived beyond the
first 4 months after the initial AF diagnosis (Dx) (right), compared with the
age- and gender-matched general Minnesota (MN) population.yccounting for 18% and 14% of the early and late deaths,
espectively.
rends in mortality after first AF diagnosis. Kaplan-
eier survival curves by 5-year periods are essentially
uperimposable (Fig. 2). Advancing age (HR per 10 years:
.95; 95% CI 1.88 to 2.03; p  0.0001) and male gender
HR 1.25; 95% CI 1.16 to 1.35; p  0.0001) were
ssociated with increased mortality risk in Cox regression
nalysis. When calendar year of AF diagnosis was added to
he model, and a main effects model was estimated, there
as no change in the overall trend in age- and gender-
djusted mortality after first AF was diagnosed observed
ver the 2 decades (HR for the year 2000 vs. 1980: 0.99;
5% CI 0.86 to 1.13; p  0.84).
nalysis of 2-way interactions. When the 2-way interac-
ions among the 3 variables (age, gender, and calendar year
f AF diagnosis) were added to the model, there was no
ignificant interaction between gender and calendar year of
F diagnosis but a significant negative interaction between
ge and calendar year of AF diagnosis (p  0.003). To
urther understand this interaction, the incidence cohort
as divided into 4 age strata (60 years, 60 to 69 years, 70
o 79 years, and80 years), and a main effects model was fit
ithin each of these strata. A significant increasing trend in
ortality was observed in patients under 60 years of age
HR 1.92; 95% CI 1.04 to 3.56; p  0.03), but no
ignificant trends could be demonstrated in the other 3 age
roups. In subjects over 60 years of age, no overall trend in
ge- and gender-adjusted mortality was observed (HR 0.98;
5% CI 0.83 to 1.09; p  0.48). Therefore, all supplemen-
ary analyses were done both overall and within 2 age strata
60 years and 60 years) (Table 2).
upplementary analyses. MORTALITY TRENDS STRATI-
IED BY AGE. For the overall group and for those over age
0, the mortality trends were similar when adjusted for age
nd gender only or when multiple clinical variables were
ncluded in the model. In contrast, for the group under 60
Figure 2 Mortality Trend of Patients Diagnosed With
First AF, Stratified by Calendar Year of AF Diagnosis
AF  atrial fibrillation.ears of age, adjustment for multiple baseline clinical vari-
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Trends in Mortality After First AF March 6, 2007:986–92bles removed the statistical significance of the increasing
rend in mortality (HR 1.56: 95% CI 0.80 to 3.03; p 
.27).
ORTALITY TRENDS STRATIFIED BY EARLY VERSUS LATE
ORTALITY AND BY PRE-EXISTING CARDIOVASCULAR DIS-
ASE. When analysis was restricted to the high-mortality
eriod (within first 4 months), to a late period (after the first
months), or to the subjects who were free of cardiovascular
iseases at the time of diagnosis of AF, there were no
ignificant trends in mortality in the overall group or in the
ver-60 age group. The only significant change identified
as an increasing trend in the under-60 age group (HR
.09; 95% CI 1.12 to 40.9; p  0.03) in the high-mortality
eriod (within first 4 months) (Table 2). Among those who
ere under 60 years of age, malignancy was the cause in 1
ut of 13 (8%) of the early deaths (within first 4 months) for
he period of 1980 to 1989, and 11 out of 36 (31%) of the
arly deaths for the period 1990 to 2000 (p  0.10). This
ortality Risk of Calendar Year 2000 Relative to 1980, Stratified b
Table 2 Mortality Risk of Calendar Year 2000 Relative to 1980
Model Subject at Risk n
Age- and gender-adjusted All eligible 4,618
Adjusted for clinical variables‡ All eligible 4,618
Adjusted for clinical variables‡ All eligible (censored at 4 months) 4,618
Adjusted for clinical variables‡ 4-month survivors 3,796
Adjusted for clinical variables‡ No CV disease§ 2,064
Hazard ratio (HR) is for calendar year 2000 compared with that in 1980; †p  0.05 for HR diffe
ate at atrial fibrillation diagnosis, and history of myocardial infarction, congestive heart failure, peri
egular alcohol use, chronic renal disease, chronic obstructive pulmonary disease, hyperthyroidis
oncurrent congestive heart failure, ischemic stroke, angina, angiographically confirmed coronary
CI  confidence interval.
ultivariable Models for Prediction of Early (Within 4 Months) or L
Table 3 Multivariable Models for Prediction of Early (Within 4 M
Variable
Overall Death
HR (95% CI) p Value
Age (per 10 yrs)* 1.79 (1.71–1.86) 0.0001
Men 1.06 (0.98–1.15) 0.17
BMI (per 5 kg/m2)* 0.90 (0.87–0.93) 0.0001
Heart rate at AF (per 10 beats/min)* 1.02 (1.01–1.03) 0.001
Prior myocardial infarction* 1.39 (1.27–1.52) 0.0001
Prior CHF* 1.34 (1.19–1.50) 0.0001
Echo-confirmed VHD 1.26 (1.16–1.38) 0.0001
Coronary revascularization 0.76 (0.67–0.86) 0.0001
Peripheral vascular disease 1.25 (1.13–1.38) 0.0001
Carotid artery disease 1.19 (1.01–1.40) 0.03
Stroke 1.29 (1.15–1.44) 0.0001
Systemic hypertension 1.28 (1.14–1.44) 0.0001
Diabetes mellitus 1.51 (1.38–1.66) 0.0001
Dyslipidemia 0.91 (0.84–0.99) 0.02
Smoking 1.17 (1.07–1.27) 0.001
Chronic renal disease* 1.57 (1.43–1.72) 0.0001
COPD* 1.41 (1.29–1.53) 0.0001
History of malignancy* 1.43 (1.32–1.55) 0.0001p  0.05 for HR different in 2 time periods of early (within first 4 months) and late (after 4 months) de
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.bservation suggested that the upward trend in early mor-
ality in the younger group might have been limited to the
ubset with malignancy. To test this possibility, analysis of
arly mortality in the younger age group was further
tratified by the presence or absence of a history of malig-
ancy. The result was a significant upward trend in early
ortality in those with malignancy (n 70), accounting for
1 early deaths (HR 16.02; 95% CI 1.95 to 131.4; p 
.008). There was no significant trend in early mortality in
hose without malignancy (n  637), accounting for 28
arly deaths (HR 1.75; 95% CI 0.47 to 6.61; p  0.39).
REDICTORS OF OVERALL, EARLY, AND LATE MORTALITY.
he predictors of overall, early (within first 4 months), and
ate (after 4 months) mortality are shown in Table 3. Age,
ut not gender, was an important predictor of death for
verall, early, and late mortality. A number of cardiovascular
isk factors and chronic disease, including pulmonary and
enal disease as well as malignancy, were predictors of
e for the Overall Population and Various Subgroups
atified by Age for the Overall Population and Various Subgroups
rall Age <60 yrs Age >60 yrs
R* (95% CI) n HR* (95% CI) n HR* (95% CI)
9 (0.86–1.13) 707 1.92† (1.04–3.56) 3,911 0.98 (0.83–1.09)
9 (0.86–1.14) 707 1.56 (0.80–3.03) 3,911 0.97 (0.84–1.12)
5 (0.73–1.22) 707 4.09† (1.12–40.9) 3,911 0.86 (0.66–1.12)
7 (0.91–1.26) 635 0.96 (0.43–2.14) 3,161 1.08 (0.91–1.28)
5 (0.75–1.21) 502 1.78 (0.63–5.02) 1,562 0.88 (0.69–1.13)
m 1.0; ‡clinical covariates selected for adjustment included age, gender, body mass index, heart
ascular disease, carotid artery disease, stroke, systemic hypertension, diabetesmellitus, smoking,
malignancy; §analysis restricted to those without cardiovascular (CV) disease including prior or
disease, and myocardial infarction.
eath (After 4 Months)
hs) or Late Death (After 4 Months)
Early Death (<4 Months) Late Death (>4 Months)
HR (95% CI) p Value HR (95% CI) p Value
1.33 (1.23–1.44) 0.0001 1.98 (1.88–2.09) 0.0001
0.99 (0.84–1.18) 0.99 1.09 (0.99–1.20) 0.07
0.80 (0.74–0.86) 0.0001 0.93 (0.89–0.97) 0.001
1.08 (1.05–1.10) 0.0001 1.00 (0.99–1.02) 0.70
1.75 (1.47–2.07) 0.0001 1.27 (1.15–1.42) 0.0001
0.90 (0.72–1.13) 0.35 1.60 (1.41–1.83) 0.0001
1.31 (1.10–1.55) 0.01 1.27 (1.15–1.41) 0.0001
0.64 (0.49–0.83) 0.001 0.80 (0.69–0.92) 0.01
1.14 (0.94–1.38) 0.19 1.30 (1.16–1.47) 0.0001
1.13 (0.84–1.53) 0.41 1.23 (1.01–1.49) 0.04
1.31 (1.06–1.62) 0.01 1.27 (1.11–1.45) 0.001
1.14 (0.89–1.45) 0.29 1.30 (1.14–1.48) 0.0001
1.52 (1.28–1.82) 0.0001 1.50 (1.35–1.67) 0.0001
0.82 (0.69–0.97) 0.02 0.95 (0.86–1.05) 0.29
1.30 (1.09–1.55) 0.01 1.12 (1.02–1.24) 0.02
1.89 (1.60–2.24) 0.0001 1.49 (1.33–1.66) 0.0001
1.14 (0.96–1.35) 0.14 1.49 (1.35–1.65) 0.0001
1.88 (1.62–2.19) 0.0001 1.29 (1.17–1.41) 0.0001y Ag
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March 6, 2007:986–92 Trends in Mortality After First AFverall mortality. Of note, malignancy and chronic renal
isease were associated with almost a 2-fold increase in risk
f early mortality, although age remained the most signifi-
ant factor for late mortality (Table 3).
iscussion
he present study showed that there was no change in the
verall age- and gender-adjusted mortality in patients diag-
osed with first AF over the 21-year period, even after
djustment for comorbidities. Our secondary analyses fur-
her demonstrated that there were no significant changes in
arly (within first 4 months) or late mortality or in the
ortality of the patients who did not have history of
ardiovascular disease at baseline.
rends in mortality over 2 decades. The present study
as not an intervention study but a longitudinal cohort
tudy with all participants selected based on first docu-
ented AF event. Most published series which reported an
mprovement in survival have been hospital-based studies
21–23), often specifically of AF complicating another event
uch as myocardial infarction or congestive heart failure
19,20). Thus, the AF events in those studies were not
ncident AF but represent a mixture of first and recurrent
F, usually surrounding specific comorbid conditions. We
ound that there was no change in the overall age- and
ender-adjusted mortality, even after adjusting for multiple
linical risk factors. Additionally, we did not find any
ignificant change in mortality trend when we limited the
nalyses to those who died within the first 4 months of AF
iagnosis, survived the first 4 months, or did not have
re-existing cardiovascular disease. The impact on mortality
rends was likely complex and multifactorial. We speculate
hat AF itself was probably not the primary cause of death
n the majority of patients but a result of an underlying
ascade of pathologic changes and events to which conven-
ional AF treatment would not make a positive impact.
herefore, although the management of AF and complica-
ions, as well as our aggressiveness in treatment of risk
actors of AF, might have changed over time, we were
nable to detect a change in the overall mortality.
In an exploratory analysis of mortality trends stratified by
ge that was motivated by the presence of a highly signifi-
ant age by calendar-year interaction term, we observed an
ncrease over time in early mortality among patients under
0 years of age which was limited to the subset of those with
history of malignancy. In addition to a significant increase
n the proportion of incident AF cases with a history of
alignancy during this period (Table 1), the proportion of
arly deaths attributable to malignancy increased from 8% to
1% in the group under 60 years of age. Whether these
bservations were related to increased survival of certain
alignancies over time, with development of AF as a
reterminal event, warrants further investigations.
redictors of overall, early, and late mortality. Atrial
brillation has previously been shown to be associated withremature death (14–18), and this was further confirmed in
he present study. We evaluated the temporal distribution of
eath, and found a clustering of death in the early period
within first 4 months), followed by an attenuated but
onetheless increased mortality risk thereafter. From our
ultivariable models, faster heart rate at AF diagnosis,
ower body mass index, history of chronic renal disease, and
alignant disease were all strongly associated with early
eath. In patients who died early after AF diagnosis, AF
epresented a preterminal event, marking the severe illness
f these patients. In contrast, cardiovascular comorbidities,
s well as chronic illness, were important predictors for late
eath, as expected to be associated with age-related AF.
tudy limitations. There were inherent biases associated
ith the retrospective design. It was possible that some
ncident AF cases were been missed, because some patients
ay not have been seen at the Mayo Clinic and some
symptomatic cases may not have come to medical atten-
ion. Detailed data with respect to cardiac function and the
se of medical therapy were not readily available, and how
hese factored into the mortality trends could not be
etermined. Also, the assessment of changes in the comor-
id conditions was difficult in part because of the changing
efinitions over time and missing laboratory data. The
opulation of Olmsted County is predominantly white, and
hether similar mortality rates and trends are present in
ther ethnic and racial groups is unknown.
onclusions
n this community-based cohort study, the mortality risk of
atients diagnosed with first AF was substantially higher
han that of the same age- and gender-matched general
opulation, especially within, but not limited to, the first 4
onths. The overall trend in age- and gender-adjusted
ortality did not change over the 21-year period, even after
ultiple adjustments. Further, we could not identify any
ignificant change in the trends of early or late mortality or
ortality of patients without pre-existing cardiovascular
isease.
eprint requests and correspondence: Dr. Teresa S. M. Tsang,
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